{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:18:47Z","timestamp":1779322727669,"version":"3.51.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,9,18]],"date-time":"2015-09-18T00:00:00Z","timestamp":1442534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,9,18]],"date-time":"2015-09-18T00:00:00Z","timestamp":1442534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aim of this study was to investigate the effects of a non-standard, intermittent imatinib treatment in elderly patients with Philadelphia-positive chronic myeloid leukaemia and to answer the question on which dose should be used once a stable optimal response has been achieved. Seventy-six patients aged \u2a7e65 years in optimal and stable response with \u2a7e2 years of standard imatinib treatment were enrolled in a study testing a regimen of intermittent imatinib (INTERIM; 1-month on and 1-month off). With a minimum follow-up of 6 years, 16\/76 patients (21%) have lost complete cytogenetic response (CCyR) and major molecular response (MMR), and 16 patients (21%) have lost MMR only. All these patients were given imatinib again, the same dose, on the standard schedule and achieved again CCyR and MMR or an even deeper molecular response. The probability of remaining on INTERIM at 6 years was 48% (95% confidence interval 35\u201359%). Nine patients died in remission. No progressions were recorded. Side effects of continuous treatment were reduced by 50%. In optimal and stable responders, a policy of intermittent imatinib treatment is feasible, is successful in about 50% of patients and is safe, as all the patients who relapsed could be brought back to optimal response.<\/jats:p>","DOI":"10.1038\/bcj.2015.75","type":"journal-article","created":{"date-parts":[[2015,9,18]],"date-time":"2015-09-18T13:22:11Z","timestamp":1442582531000},"page":"e347-e347","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment"],"prefix":"10.1038","volume":"5","author":[{"given":"D","family":"Russo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Malagola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Skert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Cancelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Turri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Pregno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Bergamaschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Fogli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Testoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"De Vivo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Castagnetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Pungolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Stagno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Martino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Intermesoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G R","family":"Cambrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Abruzzese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Tiribelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Bigazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Usala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Russo-Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Lunghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Bocchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"D'Emilio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Santini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Girasoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R Di","family":"Lorenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A Di","family":"Palma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B M","family":"Cesana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Soverini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,18]]},"reference":[{"key":"BFbcj201575_CR1","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","volume":"370","author":"R Hehlmann","year":"2005","unstructured":"Hehlmann R, Hochhaus A, Baccarani M . Chronic myeloid leukaemia. Lancet 2005; 370: 342\u2013350.","journal-title":"Lancet"},{"key":"BFbcj201575_CR2","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, O\u2019Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012; 119: 1981\u20131987.","journal-title":"Blood"},{"key":"BFbcj201575_CR3","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872\u2013884.","journal-title":"Blood"},{"key":"BFbcj201575_CR4","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","volume":"122","author":"M Hoglund","year":"2013","unstructured":"Hoglund M, Sandin F, Hellstrom K, Bj\u00f6reman M, Bj\u00f6rkholm M, Brune M et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based swedish CML registry. Blood 2013; 122: 1284\u20131292.","journal-title":"Blood"},{"key":"BFbcj201575_CR5","unstructured":"National Comprehensive Cancer Network: NCCN. Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia, version 1, 2015. www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf."},{"key":"BFbcj201575_CR6","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O\u2019Brien S, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054\u20131061.","journal-title":"Leukemia"},{"key":"BFbcj201575_CR7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jnci\/djr060","volume":"103","author":"C Gambacorti-Passerini","year":"2011","unstructured":"Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C et al. Multicenter independent assessment of outcome in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011; 103: 553\u2013561.","journal-title":"J Natl Cancer Inst"},{"key":"BFbcj201575_CR8","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","volume":"29","author":"R Hehlmann","year":"2011","unstructured":"Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Muller MC, Pletsch N et al. Tolerability-adapted imatinib 800\u2009mg\/d versus 400\u2009mg\/d versus 400\u2009mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011; 29: 1634\u20131642.","journal-title":"J Clin Oncol"},{"key":"BFbcj201575_CR9","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2013","unstructured":"Hehlmann R, Muller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study 4. J Clin Oncol 2013; 32: 415\u2013423.","journal-title":"J Clin Oncol"},{"key":"BFbcj201575_CR10","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3324\/haematol.2013.095158","volume":"99","author":"G Etienne","year":"2014","unstructured":"Etienne G, Dulucq S, Nicolini FE, Morisset F, Fort MP, Schmitt A et al. Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy. Haematol 2014; 99: 458\u2013464.","journal-title":"Haematol"},{"key":"BFbcj201575_CR11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1158\/1078-0432.CCR-13-1988","volume":"20","author":"FX Mahon","year":"2014","unstructured":"Mahon FX, Etienne G . Deep molecular response in chronic myeloid leukemia: the new goal of therapy? Clin Cancer Res 2014; 20: 310\u2013322.","journal-title":"Clin Cancer Res"},{"key":"BFbcj201575_CR12","first-page":"1","volume":"5","author":"J Apperley","year":"2014","unstructured":"Apperley J . Chronic myeloid leukemia. Semin Hematol 2014; 5: 1\u201313.","journal-title":"Semin Hematol"},{"key":"BFbcj201575_CR13","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, R\u00e9a D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic mye loid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029\u20131035.","journal-title":"Lancet Oncol"},{"key":"BFbcj201575_CR14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013; 122: 515\u2013522.","journal-title":"Blood"},{"key":"BFbcj201575_CR15","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1016\/j.ejca.2013.06.018","volume":"49","author":"N Thielen","year":"2013","unstructured":"Thielen N, van der Holt B, Cornelissen JJ, Verhof GE, Gussinklo T, Biedmond BJ et al. Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). Eur J Cancer 2013; 49: 3242\u20133246.","journal-title":"Eur J Cancer"},{"key":"BFbcj201575_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00277-015-2320-4","volume":"94","author":"FX Mahon","year":"2015","unstructured":"Mahon FX . Discontinuation of tyrosine kinase therapy in CML. Ann Hematol 2015; 94: 187\u2013193.","journal-title":"Ann Hematol"},{"key":"BFbcj201575_CR17","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New Engl J Med 2010; 362: 2251\u20132259.","journal-title":"New Engl J Med"},{"key":"BFbcj201575_CR18","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012; 119: 1123\u20131129.","journal-title":"Blood"},{"key":"BFbcj201575_CR19","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqu\u00e8 C et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014; 123: 494\u2013500.","journal-title":"Blood"},{"key":"BFbcj201575_CR20","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood.V124.21.4541.4541","volume":"124","author":"R Larson","year":"2014","unstructured":"Larson R, Kim D, Issaragrisil S, le Coutre P, Llacer Dorlhiac PE, Etienne G et al. Efficacy and safety of Nilotinib (NIL) vs Imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): long-term follow-up (f\/u) of ENESTnd. Blood 2014; 124: 4541.","journal-title":"Blood"},{"key":"BFbcj201575_CR21","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","volume":"118","author":"F Efficace","year":"2011","unstructured":"Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011; 118: 4554\u20134560.","journal-title":"Blood"},{"key":"BFbcj201575_CR22","first-page":"1395","volume":"96","author":"P Valent","year":"2011","unstructured":"Valent P . Severe adverse events associated with the use of second-line BCR\/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities. Haematol 2011; 96: 1395\u20131397.","journal-title":"Haematol"},{"key":"BFbcj201575_CR23","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.3109\/10428194.2012.695779","volume":"53","author":"JL Steegmann","year":"2012","unstructured":"Steegmann JL, Cervantes F, le Coutre P, Porkka K, Saglio G . Off-target effects of BCR-ABL1 inibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leuk Lymphoma 2012; 53: 2351\u20132361.","journal-title":"Leuk Lymphoma"},{"key":"BFbcj201575_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.critrevonc.2012.01.001","volume":"84","author":"M Breccia","year":"2012","unstructured":"Breccia M, Tiribelli M, Alimena G . Tyrosine kinase inhibitors for elderly chronic myeloid leukemia: a systematic review of efficacy and safety data. Crit Rev Oncol Hematol 2012; 84: 93\u2013100.","journal-title":"Crit Rev Oncol Hematol"},{"key":"BFbcj201575_CR25","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/leu.2013.69","volume":"27","author":"FJ Giles","year":"2013","unstructured":"Giles FJ, Mauro MJ, Hong F, Ortmann CE, McNeill C, Woodman RC et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 2013; 27: 1310\u20131315.","journal-title":"Leukemia"},{"key":"BFbcj201575_CR26","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/leu.2013.70","volume":"27","author":"TD Kim","year":"2013","unstructured":"Kim TD, Rea D, Schwarz M, Grille P, Nicolini FE, Rosti G et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinibor imatinib. Leukemia 2013; 27: 1316\u20131321.","journal-title":"Leukemia"},{"key":"BFbcj201575_CR27","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/phar.1266","volume":"33","author":"E Irvine","year":"2013","unstructured":"Irvine E, Williams C . Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Pharmacotherapy 2013; 33: 868\u2013881.","journal-title":"Pharmacotherapy"},{"key":"BFbcj201575_CR28","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","volume":"125","author":"P Valent","year":"2015","unstructured":"Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, le Coutre Pl . Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors. Blood 2015; 125: 901\u2013906.","journal-title":"Blood"},{"key":"BFbcj201575_CR29","doi-asserted-by":"publisher","first-page":"E66","DOI":"10.1002\/ajh.23938","volume":"90","author":"J Cortes","year":"2015","unstructured":"Cortes J, Mauro M, Steegmann JL, Saglio G, Malhotra R, Ukropec JA et al. Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: data from the FDA adverse event reporting system. Am J Hematol 2015; 90: E66\u2013E72.","journal-title":"Am J Hematol"},{"key":"BFbcj201575_CR30","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","volume":"121","author":"Experts in Chronic Myeloid Leukemia","year":"2013","unstructured":"Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013; 121: 4439\u20134442.","journal-title":"Blood"},{"key":"BFbcj201575_CR31","doi-asserted-by":"publisher","first-page":"5138","DOI":"10.1182\/blood-2013-01-480194","volume":"121","author":"D Russo","year":"2013","unstructured":"Russo D, Martinelli G, Malagola M, Skert C, Soverini S, Iacobucci I et al. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. Blood 2013; 121: 5138\u20135144.","journal-title":"Blood"},{"key":"BFbcj201575_CR32","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson GE et al. Prognostic discrimination in \"good-risk\" chronic granulocytic leukemia. Blood 1984; 63: 789\u2013799.","journal-title":"Blood"},{"key":"BFbcj201575_CR33","doi-asserted-by":"publisher","first-page":"4939","DOI":"10.1182\/blood-2009-07-229864","volume":"114","author":"N Testoni","year":"2009","unstructured":"Testoni N, Marzocchi G, Luatti S, Amabile M, Baldazzi S, Stacchini M et al. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood 2009; 114: 4939\u20134943.","journal-title":"Blood"},{"key":"BFbcj201575_CR34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A, Brandford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:review and recommendations for harmonizing current methodology for detecting BCR\u2014ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28\u201337.","journal-title":"Blood"},{"key":"BFbcj201575_CR35","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NC Cross","year":"2012","unstructured":"Cross NC, White HE, Muller MC, Saglio G, Hochhaus A . Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012; 26: 2172\u20132175.","journal-title":"Leukemia"},{"key":"BFbcj201575_CR36","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00277-015-2315-1","volume":"94","author":"NC Cross","year":"2015","unstructured":"Cross NC, Hochhaus A, M\u00fcller MC . Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization. Ann Hematol 2015; 94: 219\u2013225.","journal-title":"Ann Hematol"},{"key":"BFbcj201575_CR37","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","volume":"118","author":"S Soverini","year":"2011","unstructured":"Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011; 118: 1208\u20131215.","journal-title":"Blood"},{"key":"BFbcj201575_CR38","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"PM Kaplan","year":"1958","unstructured":"Kaplan PM, Meier HT . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457\u2013481.","journal-title":"J Am Stat Assoc"},{"key":"BFbcj201575_CR39","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer B . Estimation of failure probabilities in the presence of competing risk: new representations of old estimators. Stat Med 1999; 18: 695\u2013706.","journal-title":"Stat Med"},{"key":"BFbcj201575_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bjh.12892","volume":"166","author":"DM Ross","year":"2014","unstructured":"Ross DM, Hughes TP . How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia. B J Haematol 2014; 166: 3\u201311.","journal-title":"B J Haematol"},{"key":"BFbcj201575_CR41","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.leukres.2013.01.006","volume":"37","author":"A Quint\u00e1s-Cardama","year":"2013","unstructured":"Quint\u00e1s-Cardama A, Jabbour EJ . Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib. Leuk Res 2013; 37: 487\u2013495.","journal-title":"Leuk Res"},{"key":"BFbcj201575_CR42","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1182\/asheducation-2013.1.168","volume":"2013","author":"T Hughes","year":"2013","unstructured":"Hughes T, White D . Which TKI? An embarrassment of riches for chronic myeloid leukemia patients. Hematology Am Soc Hematol Educ Program 2013; 2013: 168\u2013175, Presented at the 55th American Society of Hematology Meeting; 7\u201310 December; New Orleans, Louisiana, USA.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"BFbcj201575_CR43","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1182\/blood-2014-07-590315","volume":"125","author":"DT Yeung","year":"2015","unstructured":"Yeung DT, Osborn MP, White DL, Brandford S, Braley J, Herschtal A et al. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood 2015; 125: 915\u2013923.","journal-title":"Blood"},{"key":"BFbcj201575_CR44","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1200\/JCO.2011.36.0693","volume":"29","author":"E Jabbour","year":"2011","unstructured":"Jabbour E, Kantarjian HM, O\u2019Brien S, Shan J, Quintas-Cardama A, Garcia-Manero G et al. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response? J Clin Oncol 2011; 29: 4260\u20134265.","journal-title":"J Clin Oncol"},{"key":"BFbcj201575_CR45","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/leu.2011.217","volume":"26","author":"PJ Shami","year":"2012","unstructured":"Shami PJ, Deininger M . Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. Leukemia 2012; 26: 214\u2013224.","journal-title":"Leukemia"},{"key":"BFbcj201575_CR46","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","volume":"113","author":"L Noens","year":"2009","unstructured":"Noens L, van Lierde MA, De Bock R, Verhoef G, Zach\u00e8e P, Berneman Z et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009; 113: 5401\u20135411.","journal-title":"Blood"},{"key":"BFbcj201575_CR47","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukaemia who achieve complete cytogenetic response on imatinib. J Clin Oncol 2010; 28: 2381\u20132388.","journal-title":"J Clin Oncol"},{"key":"BFbcj201575_CR48","doi-asserted-by":"crossref","unstructured":"Mahon FX, Richter J, Guilhot J, Muller MC, Dietz C, Porkka K et al. Interim analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia: the EURO-SKI study. Blood 2014, 124 (Abs 151).","DOI":"10.1182\/blood.V124.21.151.151"},{"key":"BFbcj201575_CR49","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1200\/JCO.2014.55.6910","volume":"32","author":"J Richter","year":"2014","unstructured":"Richter J, S\u00f6derlund S, L\u00fcbking A, Dreimane A, Lotfi K, Markevarn B et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol 2014; 32: 2821\u20132823.","journal-title":"J Clin Oncol"},{"key":"BFbcj201575_CR50","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/leu.2015.73","volume":"29","author":"V Hoffmann","year":"2015","unstructured":"Hoffmann V, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D et al. The EUTOS population-based registry incidence and clinical characteristics of 2094 CML patients in 20 European countries. Leukemia 2015; 29: 1336\u20131343.","journal-title":"Leukemia"},{"key":"BFbcj201575_CR51","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","volume":"118","author":"JC Chomel","year":"2011","unstructured":"Chomel JC, Bonnet ML, Sorel N, Bertrand A, Meunier MC, Fichelson S et al. Leukemia stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 2011; 118: 3657\u20133660.","journal-title":"Blood"},{"key":"BFbcj201575_CR52","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","volume":"118","author":"S Chu","year":"2011","unstructured":"Chu S, McDonald T, Lin A, Chakraborty S, Huang Q, Snyder DS et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 2011; 118: 5565\u20135572.","journal-title":"Blood"},{"key":"BFbcj201575_CR53","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1182\/asheducation-2013.1.189","volume":"2013","author":"W Ahmed","year":"2013","unstructured":"Ahmed W, Van Etten RA . Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond. Hematology Am Soc Hematol Educ Program 2013; 2013: 189\u2013200, Presented at the 55th American Society of Hematology Meeting; 7\u201310 December, New Orleans, Louisiana, USA.","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201575.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201575","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201575.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T10:02:55Z","timestamp":1672912975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,18]]},"references-count":53,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,9]]}},"alternative-id":["BFbcj201575"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2015.75","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,18]]},"assertion":[{"value":"14 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Domenico Russo, Patrizia Pregno and Simona Soverini receives compensation as a consultant for Novartis, Bristol-Myers Squibb and Ariad. Elisabetta Abruzzese receives compensation as a consultant for Ariad, Bristol-Myers Squibb, Novartis, Takeda and Pfizer. Giovanni Martinelli receives compensation as a consultant for Novartis, Bristol-Myers Squibb and Pfizer. Gianantonio Rosti, Fausto Castagnetti and Michele Baccarani receives compensation as a consultant for Novartis, Ariad, Bristol-Myers Squibb and Pfizer. Mario Tiribelli receives compensation as a consultant for Novartis, BMS and Ariad. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}